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Abstract Hemopexin, the heme-binding serum glycoprotein, 
exhibits a complex electrophoretic pattern on two-dimensional 
immunoelectrophoresis on agarose gels into which hyaluronic 
acid is incorporated in the first and monospecific anti-hemopexin 
in the second dimension. This heterogeneity reflects a range of 
interactions of hemopexin isoforms with hyaluronic acid. 
Electrophoretic patterns of individual human sera greatly differ 
in their contents of hyaluronan-interacting hemopexin species. 
Hemopexin itself has no hyaluronidase activity. 
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1. Introduction 
Hemopexin is the heme-binding serum glycoprotein which 
is responsible for the transport of heme released into the 
blood stream from hemolysed erythrocytes to the liver for 
further metabolism [1]. The physiological sense of this meta- 
bolic pathway is to save iron which would otherwise scape 
from the body [2] and to prevent oxic oxidative ffects of free 
heme on the tissues [3]. The heme scavenging property of 
hemopexin is well known [4]. Additional physiological func- 
tions of hemopexin have recently been suggested, i.e., involve- 
ment in neuron repair [5,6] and the hyaluronidase activity (the 
ability to hydrolyze polymeric hyaluronic acid). The latter 
function was derived from the observed identity of hemopexin 
and serum hyaluronidase [7]. 
The present communication presents evidence that purified 
hemopexin as well as the variant fraction of hemopexin con- 
tained in human serum have an affinity to hyaluronan. This 
property may be responsible for its accumulation i  healing 
neuronal tissues. No hyaluronidase activity was, however, ob- 
served in purified hemopexin. This activity occurred in some 
hemopexin preparations due to contaminating hyaluronidases. 
2. Materials and methods 
2.1. Materials 
Hyaluronic acid from human umbilical cord and chondroitin sul- 
fate A from bovine trachea were purchased, as the sodium salts, from 
Sigma-Aldrich (Czech Republic). 
Human hemopexin was isolated from the serum of healthy individ- 
uals by sequential chromatography on S-Sepharose FF and Blue Se- 
pharose CL-6B [8]. 
2.2. Electrophoretic methods 
Crossed affinity immunoelectrophoresis in agarose gel was per- 
formed according to Weeke [9] using a Multiphore apparatus (Phar- 
macia, Sweden). Hyaluronic acid (0.5 mg/ml) was incorporated into 
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the agarose gel in the first and 150 ~1 of polyclonal anti-human he- 
mopexin antiserum (SEVAC, Prague, Czech Republic) into the second 
dimension. 
Substrate gel electrophoresis (hyaluronan-PAGE) was performed in 
7.5% native polyacrylamide g ls containing 0.17 mg/ml hyaluronic 
acid [10] using Mini-Protean II apparatus (BioRad, USA). 15 /.tl of 
2.5 mg/ml hemopexin solution or of 1/20 diluted human serum was 
applied. The hyaluronidase activity was assessed by Alcian blue stain- 
ing of the gels incubated for 12 h at 37°C in 0.1 M Na formate [11]. In 
parallel, the gels were stained with Coomassie blue R-250. 
3. Results 
The pattern of hemopexin, of human sera (Fig. 1A,B) and 
purified protein (Fig. 1C), in crossed affinity immunoelectro- 
phoresis with hyaluronan, shows bi- to multiphasicity. Omis- 
sion of hyaluronan from the first dimension gel resulted in a 
single symmetrical immunoprecipitation arc, observed for the 
human sera (Fig. la,b) and purified hemopexin (Fig. lc). 
Components immunologically identical or largely homologous 
with hemopexin appear to be present in the sera which exhibit 
hyaladherent properties demonstrated by the inhomogeneous 
retardation of hemopexin on hyaluronan-containing gels. 
Both patterns and contents of anodically slower components 
differ markedly among individual sera as well as among in- 
dividual hemopexin isolations, comprising 10-60% of total 
hemopexin. Such a complex immunoprecipitation pattern as 
that of hemopexin was not observed for any other serum 
protein. All serum proteins, however, are to some extent re- 
tarded on gels containing hyaluronan as compared to gels 
without hyaluronan (not shown), undoubtedly due to a high 
electroosmotic flow caused by immobilized negatively charged 
hyaluronic acid. 
To investigate whether the microheterogeneity of hemopex- 
in is specific for its interaction with hyaluronan we also in- 
corporated into the first dimension chondroitin sulfate, an- 
other negatively charged glycosaminoglycan. The presence of 
this compound causes neither a shift in net mobility nor he- 
mopexin heterogeneity. We conclude that the observed multi- 
phasic electrophoretic patterns reflect specific hyaluronan he- 
mopexin interactions. 
Several preparations of purified hemopexin were subjected 
to hyaluronan-PAGE and developed with Alcian blue for 
hyaluronidase activity (Fig. 2A) and with Coomassie blue 
staining for protein (Fig. 2B). Hyaluronidase (clear zones in 
Fig. 2A) is present in three out of seven hemopexin prepara- 
tions. The electrophoretic mobility of the enzyme by itself, 
however, is distinctly slower than that of hemopexin and 
equal to that of hyaluronidase contained in the human serum 
(well 8, Fig. 2A). Since hemopexin has some affinity to Alcian 
blue (dark zones in Fig. 2A), a comparison can also be made 
on the Alcian blue stained gels. Obviously, hemopexin by 
itself has no hyaluronidase activity. Rather, serum hyaluroni- 
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molecules is retarded on hyaluronan-containing gels the hyal- 
uronan-binding motif cannot be solely responsible for the 
multiphasicity of the hemopexin patterns. The well-known 
hemopexin microheterogeneity in composition of five oligo- 
saccharide chains [18] may result in subtle conformational 
differences of hemopexin polypeptide which are reflected in 
heterogeneous ligand binding. Consequently, the individual 
hemopexin populations are to various extents retarded on 
hyaluronan-containing gels. The great variety in the contents 
of HA-interacting hemopexin species in the individual sera 
will further be explored. 
The observed interactions of hemopexin(-like?) species with 
hyaluronan may explain the long-term accumulation of hemo- 
pexin in hyaluronic acid rich tissues, i.e. healing neurons [5,6] 
and brain [19]. 
Hyaluronidase activity, if present in hemopexin prepara- 
tions, was due to contaminanting hyaluronidases. It was a 
minor contaminant as 40 Ixg of protein had to be applied 
per well of hyaluronan-PAGE the hyaluronidase activity to 
be observed. 
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}-ig. 1. Electrophoretic patterns of hemopexin, in serum or purified. 
( rossed immunoelectrophoresis of human sera (A, B) and of puri- 
fi zd human hemopexin (C) performed with gels that contained hyal- 
t~ "onic acid (0.5 mg/ml) in the first dimension and polyclonal anti- 
haman hemopexin antiserum in the second dimension. Panels a-c 
slow control experiments performed with gels not containing hyal- 
t~ronic acid. 3 ~tl of serum or 1 mg/ml hemopexin was applied. 
case as a contaminant or possibly a complex may escort he- 
lopexin during isolation procedures. 
4. Discuss ion 
Hemopexin is a heme-scavenging serum glycoprotein. Its 
tarbohydrate moiety consists of five oligosaccharide chains 
[/2] and comprises about 20% of the protein molecular mass 
[ t3]. Hemopexin single polypeptide chain is composed of two 
/ omologous domains joined by a hinge region [14]. A 'hemo- 
t~exin domain' is also contained in a number of proteins func- 
x ionally unrelated to hemopexin, such as matrix degrading 
~aetalloproteinases (collagenases, gelatinases, stromelysins) 
!15] and the cell adhesion plasma protein vitronectin [16]. 
~(ecently, a common hyaluronan binding motif B(XT)B (B is 
~,rg or Lys and X any non-acidic amino acid residue) was 
l ound in the hyaluronan-binding proteins RHAMM, CD44 
:~nd the link protein [17] as well as in human, rat, rabbit 
~nd pig hemopexins [7]. The B(XT)B motif may be responsible 
I or the hyaluronan-binding property of hemopexin. The pro- 
1,ortion of this binding property in individual human sera as 
well as in isolated hemopexin preparations ranges from 10 to 
~,0% of the total hemopexin. As only a fraction of hemopexin 
B 
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.-.-41- 
Fig. 2. Hyaluronidase activity testing of hemopexin preparations 
and a representative s rum. A: Individual hemopexin preparations 
(lanes 1-7) and a representative human serum (lane 8) on substrate- 
PAGE. The 7.5% 'native' polyacrylamide gel contained 0.17 mg/ml 
hyaluronic acid and was stained for hyaluronidase activity with A1- 
cian blue. The positions of hyaluronidase activity (clear bands) and 
of hemopexin (dark bands) are depicted. B: Control PAGE gel 
stained with Coomassie blue R-250. 
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